Latest / Community Health Media
HER2-Low & Ultralow Breast Cancer: Testing & T-DXd with Drs. Neil Iyengar & Sunil Badve
Why does accurate HER2 testing matter more than ever for patients with breast cancer?
Dr. Neil Iyengar and Dr. Sunil Badve discuss the evolving understanding of HER2-low and HER2-ultralow breast cancer and how advances in pathology and clinical evidence are expanding the population of patients who may be candidates for trastuzumab deruxtecan (T-DXd).
Drawing on findings from DESTINY-Breast04 and DESTINY-Breast06, they explore how HER2 assessment has moved beyond the traditional amplified versus non-amplified framework, why accurately identifying low levels of HER2 expression matters, and how…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.